American Society of Hematology

Figure 3

$Figure 3. CD30 expression per IHC assessed by visual and computer-assisted methods. An 83-year-old male with relapsed DLBCL achieved a CR after 2 cycles of treatment and had (A) 0% CD30 expression by visual central review and (B) 1.4% CD30 expression by computer-assisted methods. He discontinued treatment after 7 cycles of therapy as a result of grade 2 PSN and subsequently progressed (response duration ∼4 months). A 76-year-old male with refractory DLBCL achieved a CR after 2 cycles of treatment and had (C) 1% CD30 expression by visual central review and (D) 34% CD30 expression by computer-assisted methods. He discontinued treatment after 17 cycles of therapy as a result of PD (response duration ∼11 months).$

CD30 expression per IHC assessed by visual and computer-assisted methods. An 83-year-old male with relapsed DLBCL achieved a CR after 2 cycles of treatment and had (A) 0% CD30 expression by visual central review and (B) 1.4% CD30 expression by computer-assisted methods. He discontinued treatment after 7 cycles of therapy as a result of grade 2 PSN and subsequently progressed (response duration ∼4 months). A 76-year-old male with refractory DLBCL achieved a CR after 2 cycles of treatment and had (C) 1% CD30 expression by visual central review and (D) 34% CD30 expression by computer-assisted methods. He discontinued treatment after 17 cycles of therapy as a result of PD (response duration ∼11 months).

This Feature Is Available To Subscribers Only